Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study

Edward Litton1,2,14*, Stuart Baker3, Wendy Erber4, Shannon Farmer5, Janet Ferrier1, Craig French6,7, Joel Gummer8, David Hawkins9, Alisa Higgins10, Axel Hofmann5, Bart De Keulenaer1, Julie Mc Morrow11, John K. Olynyk12, Toby Richards13, Simon Towler1, Robert Trengove8, Steve Webb2,11, on behalf of the IRONMAN Study investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group

Abstract

Background: Both anaemia and red blood cell (RBC) transfusion are common and associated with adverse outcomes in patients admitted to the intensive care unit (ICU). The aim of this study was to determine whether serum hepcidin concentration, measured early after ICU admission in patients with anaemia, could identify a group in whom intravenous (IV) iron therapy decreased the subsequent RBC transfusion requirement.

Methods: We conducted a prospective observational study nested within a multicenter randomized controlled trial (RCT) of IV iron versus placebo. The study was conducted in the ICUs of four tertiary hospitals in Perth, Western Australia. Critically ill patients with haemoglobin (Hb) of < 100 g/L and within 48 h of admission to the ICU were eligible for participation after enrolment in the IRONMAN RCT. The response to IV iron therapy compared with placebo was assessed according to tertile of hepcidin concentration.

Results: Hepcidin concentration was measured within 48 h of ICU admission in 133 patients. For patients in the lower two tertiles of hepcidin concentration (< 53.0 μg), IV iron therapy compared with placebo was associated with a significant decrease in RBC transfusion requirement [risk ratio 0.48 (95% CI 0.26–0.85), p = 0.013].

Conclusions: In critically ill patients with anaemia admitted to an ICU, baseline hepcidin concentration predicts RBC transfusion requirement and is able to identify a group of patients in whom IV iron compared with placebo is associated with a significant decrease in RBC transfusion requirement.

Trial registration: Australian New Zealand Clinical Trials Registry: ANZCTR12612001249 Registered 26/11/2012

Keywords: Anaemia, Critical care, Hepcidin, Intravenous iron, Red blood cell transfusion

Background

Anaemia is common in patients admitted to the intensive care unit (ICU) and is associated with adverse outcomes [1, 2]. Despite evidence to support a restrictive red blood cell (RBC) transfusion threshold, anaemia is also the most common indication for RBC transfusion in the ICU, itself associated with increased morbidity and mortality [3].

In non-critically ill patients, intravenous (IV) iron therapy is effective in promoting erythropoiesis and decreasing RBC transfusion requirement [4]. However, recent randomized controlled trials (RCTs) of IV iron therapy in critically ill patients have not demonstrated benefit [5, 6]. This may be because critical illness results in an acute inflammatory response that confounds the interpretation of standard, clinically available measures of iron deficiency used in these studies. By contrast, the serum concentration of hepcidin, a key regulator of iron metabolism, decreases in response to iron-restricted erythropoiesis, even in the presence of inflammation [7]. Hepcidin is a small peptide secreted predominantly by...
the liver and acts by blocking duodenal iron absorption and decreasing availability of iron stored in hepatocytes and macrophages to red cell precursors. Although hepcidin may be more accurate in predicting an increase in red blood cell production in response to IV iron, prospective clinical data is lacking.

The primary aim of this study was to determine whether low serum hepcidin concentration could identify a subset of critically ill patients with anaemia in whom IV iron therapy was effective in reducing RBC transfusion requirement.

**Methods**

The study was a prospective cohort study, nested within the IRONMAN RCT, the protocol and primary results of which have previously been published [5, 8]. Briefly, the IRONMAN RCT enrolled adult patients who were within 48 h of admission to ICU, had a hemoglobin (Hb) of less than 100 g/L, and were anticipated to require ICU care beyond the next calendar day. Exclusion criteria included suspected or confirmed severe sepsis, a ferritin greater than 1200 ng/mL or transferrin saturation greater than 50%. Participants were randomised in a 1:1 ratio to receive either 500 mg IV ferric carboxymaltose or placebo and were followed up to hospital discharge. Human Research Ethics Committee approval was obtained at all sites prior to commencement, and prospective consent was obtained from all participants or their legal surrogates.

For this nested cohort study, blood was collected for serum hepcidin measurement immediately following enrolment and prior to study drug administration. Hepcidin-25 was isolated from blood for quantitation by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-qTOF-MS), using a Waters Synapt G2S (Waters, Manchester, UK) as previously described [9, 10]. Hepcidin was isolated by solid phase extraction following the initial addition of a synthetic human hepcidin (13C18,15N3) peptide internal standard (Peptides International, Kentucky, USA) and removal of the more abundant polypeptides by organic solvent precipitation and centrifugation. The accurate mass measurement of the precursor hepcidin-25 [M+5H]5+ ion was confirmed against a hepcidin-25 standard (Peptides International, Kentucky, USA) and further by MS/MS. Quantitation was by reference to a human hepcidin-25 (13C18,15N3) calibration, prepared in human serum.

The primary objective was to determine whether hepcidin concentration could identify a group of critically ill patients for whom IV iron therapy was effective in decreasing the risk of RBC transfusion. The secondary objective was to develop a prognostic model for RBC transfusion quantity in patients admitted to the ICU.

**Statistical analysis**

Continuous variables were reported as mean (± SD) or median and interquartile range (IQR), with between-group differences analyzed using Student's t test or the Wilcoxon rank-sum test for apparently normal and
non-normally distributed data respectively. Categorical variables were reported as proportion and analyzed using the $\chi^2$ test or Fischer exact test as appropriate. Data was censored at 60 days after enrolment for RBC transfusion Hb concentration and vital status.

The relationship between hepcidin concentration and response to IV iron therapy was examined using similar methodology to a previously published RCT of IV iron in patients with chemotherapy-induced anaemia conducted by Steensma et al. [11]. Similar to this methodology, patients were first stratified by tertile of baseline hepcidin concentration then combined. The incident risk ratio for RBC transfusion was then compared between those who were randomized to receive IV iron and those who received placebo. The relationship between IV iron therapy and RBC transfusion quantity across the range of hepcidin values was further explored by locally weighted scatterplot smoothing (LOWESS) [12]. Receiver-operator characteristic curve analysis was not undertaken because the IRONMAN RCT demonstrated nearly identical overall proportions of patients transfused in the two groups.

The model to predict subsequent RBC transfusion quantity in patients admitted to the ICU was developed using negative binomial univariate and multivariate analyses. Variables with a $p$ value of $<0.05$ on univariate analysis were included in a multivariable analysis with backwards selection with an alpha of 0.05. Interaction was assessed using multivariable fractional polynomials to account for potential non-linear relationships. Significant interactions ($p$ value of $<0.05$) were examined graphically, and a final model was then produced. The relative prognostic value with and without baseline hepcidin concentration included was assessed using Akaike information criterion (AIC).

Outcome data was censored at 60 days after enrolment. A two-sided $p$ value of 0.05 or less was considered to be statistically significant. All analyses were conducted with Stata Version 14 StataCorp College Station, TX77845, USA.

### Table 1 Baseline characteristics

| Characteristic* | Outcome (n = 133) |
|-----------------|-------------------|
| Age—years       | 62 (41–73)        |
| Male gender—no. (%) | 91 (68)        |
| ICU admission source—no (%) | 24 (18) |
| Emergency department | 24 (18) |
| Hospital ward | 8 (6) |
| Operating theater | 97 (73) |
| Other hospital | 4 (3) |
| ICU admission type—no (%) | 17 (13) |
| Medical | 17 (13) |
| General surgical | 20 (15) |
| Cardiothoracic | 49 (37) |
| Trauma | 42 (32) |
| Neurosurgical | 5 (4) |
| APACHE II score | 12 (9–17) |
| SOFA score | 6 (4–9) |
| Prior RBC transfusion—no (%) | 30 (23) |
| Haemoglobin—g/L | 88 (81–94) |
| Mean corpuscular volume—fl | 91 (88–94) |
| C reactive protein—mg/L | 110 (48–170) |
| Iron—mcg/dL | 3 (2–6) |
| Ferritin—mg/ml* | 260 (161–437) |
| Transferrin—mg/dL | 17 (15–20) |
| Transferrin saturation—% | 9 (6–16) |
| Soluble transferrin receptor—mg/L | 1.81 (1.28–2.44) |
| Hepcidin—µg/mL | 34.9 (17.3–69.2) |
| Tertile 1—(0–20.08) | 106 (42–15.6) |
| Tertile 2—(20.09–53.00) | 34.9 (27.1–48.5) |
| Tertile 3—(53.01–163.46) | 81.2 (69.2–97.9) |

*Median and interquartile range (IQR) unless otherwise reported

### Hepcidin and prediction of response to IV iron

Of the 88 patients in the lower two tertiles of hepcidin concentration (0 to 53.0 µg/L), 44 received IV iron therapy and 44 received placebo. In patients with a low hepcidin concentration ($\leq$ 53.0 µg/L), the relative risk (RR) of RBC transfusion associated with IV iron was 0.48 (95% CI 0.26–0.85), $p = 0.013$. In patients with a high hepcidin level (> 53.0 µg/L), there was no significant association between IV iron therapy and risk of RBC transfusion, RR 1.33 (95% CI 0.57–3.08), $p = 0.518$. The association between IV iron therapy and RBC transfusion by tertile of hepcidin concentration is provided in Table 2. The association between hepcidin concentration and RBC transfusion quantity in patients who received IV iron compared with placebo is represented by the LOWESS plot in Fig. 2.
IV iron therapy compared with placebo was not associated with a significant increase in Hb for those in the lower two tertiles of hepcidin values [mean increase Hb 3 g/L (95% CI −3–10), \( p = 0.361 \)]. There was no significant correlation between hepcidin and concurrent Hb, ferritin, transferrin saturation, soluble transferrin receptor or C reactive protein. There was also no significant difference in iron, transferrin saturation, ferritin or transferrin receptor levels associated with lower versus higher hepcidin tertile (see Additional file 1).

**Predicting RBC transfusion quantity**

The complete list of variables assessed on univariate analysis and those added to the initial multivariable model is provided in Additional file 1. ICU admission related to trauma, baseline Hb < 80 g/L, lower transferrin saturation and lower hepcidin concentration were found to predict increased risk of RBC transfusion and were retained in the final multivariable model. There was a significant interaction between Hb and hepcidin concentrations in predicting the risk of RBC transfusion (likelihood ratio test for significance of interaction \( p = 0.0462 \)), see Additional file 1: Figure S1. For patients with a Hb \( \geq 80 \) g/L, each 10 μg/mL increase in hepcidin concentration was associated with a risk ratio of RBC transfusion of 1.09 (95% CI 1.01–1.18, \( p = 0.034 \)). However, for patients with a Hb < 80 g/L, there was no significant association between hepcidin concentration and risk of RBC transfusion [RR 0.95 (95% CI 0.84–1.07), \( p = 0.387 \)]. The variables included in the final model are

### Table 2 Hepcidin and risk of RBC transfusion with IV iron therapy

| Variable                  | IV iron | Placebo | Risk ratio (95% CI) | \( p \) value |
|---------------------------|---------|---------|--------------------|--------------|
| Hepcidin \( \leq 53.0 \) μg/L |         |         |                    |              |
| Number RBC units/patients | 38/44   | 80/44   |                    |              |
| Median RBC units (IQR)    | 1 (0–2) | 1 (0–3) | 0.48 (0.26–0.85)   | 0.013        |
| Hepcidin 1st tertile (0–20.1 μg/L) |         |         |                    |              |
| Number RBC units/number patients | 23/22 | 35/21 |                    |              |
| Median RBC units (IQR)    | 1 (0–2) | 0 (0–2) | 0.63 (0.26–1.50)   | 0.293        |
| Hepcidin 2nd tertile (20.1–53.0 μg/L) |         |         |                    |              |
| Number RBC units/number patients | 15/22 | 45/23 |                    |              |
| Median RBC units (IQR)    | 0 (0–1) | 1 (0–3) | 0.35 (0.16–0.77)   | 0.009        |
| Hepcidin 3rd tertile (> 53.0 μg/L) |         |         |                    |              |
| Number RBC units/number patients | 43/22 | 34/23 |                    |              |
| Median RBC units (IQR)    | 1 (0–3) | 1 (0–3) | 1.33 (0.57–3.08)   | 0.518        |

*RBC red blood cell, IQR interquartile range*
provided in Table 3. AIC with hepcidin in the model was 415.14 versus 468.16 with hepcidin removed.

Discussion

We found that serum hepcidin concentration identified a subset of anaemic, critically ill patients in whom IV iron therapy was effective in reducing RBC transfusion requirement. These findings are important when considering the dose-response relationship between increasing RBC transfusion quantity and worse clinical outcomes and also due to the scarcity and cost of RBC transfusion. In addition to predicting the effectiveness of IV iron in critically ill patients, we also found that hepcidin concentration was an independent predictor of RBC transfusion requirement but that the association was modified by Hb levels.

Although Lasocki et al. have described low hepcidin concentrations in some critically ill patients with anaemia, there is limited data exploring whether hepcidin can be used to guide treatment decisions [7]. Steensma et al. found that hepcidin concentration could predict response to IV iron therapy in patients with chemotherapy-induced anaemia [11]. In our study, the median C reactive protein was 110 mg/L but did not correlate with hepcidin concentration, suggesting that even in the presence of inflammation, measurement of hepcidin is useful in identifying critically ill patients in whom IV iron therapy is likely to reduce RBC transfusion requirement [13]. Our findings also support further investigation into the role of hepcidin antagonists in patients with elevated hepcidin [14].

Hepcidin synthesis is finely regulated and induced by both inflammation and iron overload [15]. Hepcidin levels have been shown to be the predominant predictor of erythrocyte iron incorporation in African children with anaemia [16]. Amongst adult patients admitted to the ICU, Tacke et al. have demonstrated an association between markers of increased iron availability and mortality [17]. It is plausible that using hepcidin concentration to target IV iron therapy in critically ill patients can also reduce the potential risk of initiating or exacerbating infection associated with both excessively high free iron levels and iron deficiency.

Accurate prediction of RBC transfusion quantity could provide an additional method to target IV iron therapy in critically ill patients. In the IRONMAN RCT, subgroup analysis did not suggest a differential effect of IV iron related to transferrin saturation or ferritin concentration [5]. Building on these findings, the current study found no significant difference in iron indices based on hepcidin tertile or correlation between iron indices and hepcidin. Although iron-restricted erythropoiesis is not present in all critical patients who require RBC transfusion, our study found that hepcidin was an independent predictor of subsequent transfusion. Although our model requires validation, a metric of observed versus predicted RBC transfusion may also be useful as a quality metric.

Future studies must also address the substantial variation that currently exists in hepcidin assays and reference ranges that makes comparison between studies difficult [14]. A reliable point of care hepcidin test is necessary to provide results in a clinically useful timeframe. The ongoing HEPCIDANE RCT (NCT02276690) of hepcidin-guided management of anaemia in critically ill patients will address some of these issues.

Limitations

Our study was limited to patients with an Hb < 100 g/L and did not enroll patients with sepsis. Whether hepcidin measurement is useful in these patients remains uncertain. Although soluble transferrin receptor levels were not found not to be predictive of RBC transfusion requirement in our study, other assays with potential diagnostic benefit including zinc protophoryn were not assessed. However, given the central role of hepcidin in iron metabolism, it is unlikely that other assays provide superior diagnostic utility. The relatively small number of participants precluded the use of methods to reduce the risk of over-fitting of the statistical models, and larger studies are required to validate the findings. Finally, the current study only assessed the use of hepcidin at a single point in time. Greater understanding is required of how hepcidin levels change over time including the effect interventions such as RBC transfusion and IV iron therapy.

Conclusion

In patients with anaemia admitted to the ICU, hepcidin measurement can identify a group of patients in whom IV iron therapy decreases RBC transfusion requirement.

| Table 3 Final multivariate model—Independent predictors of RBC transfusion |
|--------------------------------|----------------------|----------------------|----------------------|
| Characteristic (n = 133) | Coefficient (95% CI) | Risk ratio (95% CI) | p value |
| ICU admission type—trauma vs non trauma | 0.833 (0.382–1.285) | 2.30 (1.46–3.61) | < 0.001 |
| Haematoglobin > 80 g/L—yes vs no | −0.99 (−1.493 to −0.493) | 0.37 (0.22–0.61) | < 0.001 |
| Transferrin saturation—per 10% increase | 0.237 (0.082–0.391) | 1.27 (1.09–1.48) | 0.003 |
| Hepcidin—per 10 μg/ml increase | 0.086 (0.030–0.142) | 1.09 (1.03–1.15) | 0.002 |

CI confidence interval, ICU intensive care unit. Constant for model 0.088 (95% CI −0.398–0.575)

*Likelihood ratio test for significance of interaction between haemoglobin as a continuous variable and hepcidin concentration in predicting the risk of RBC transfusion p = 0.0462. For patients with a haemoglobin < 80 g/L, there was no significant association between hepcidin concentration and risk of RBC transfusion (RR 0.95 (95% CI 0.84–1.07), p = 0.387)
Additional file

Additional file 1: Figure S1. Relationship between hepcidin concentration and RBC transfusion, moderated by haemoglobin concentration. Hb Haemoglobin, RBC red blood cell. Table S1. Iron indices according to hepcidin levels. Table S2. Univariate analysis of variables associated with risk of RBC transfusion. CI confidence interval, ICU intensive care unit, APACHE acute physiology and chronic health evaluation, SOFA sequential organ failure assessment. Variables in bold added to the initial multivariable model. (DOCX 108 kb)

Abbreviations
CI: Confidence interval; Hb: Haemoglobin; ICU: Intensive care unit; IQR: Interquartile range; IV: Intravenous; RBC: Red blood cell; RCT: Randomized controlled trial; RR: Risk ratio; SD: Standard deviation

Acknowledgements
The authors would like to thank Associate Professor KM Ho and the Centre for Applied Statistics, University of Western Australia for their review of the statistical aspects of the manuscript. The IRONMAN RCT is part of the Blood – CRE, Centre of Research Excellence for Patient Blood Management in Critical Illness and Trauma. The authors would also like to thank our collaborators Dr. Andy Chapman, Royal Perth Hospital, Perth, Western Australia; Ms. Elizabeth Jenkinson, Royal Perth Hospital, Perth, Western Australia; Ms. Anne Marie Palermo, Fremantle Hospital, Fremantle, WA; Ms. Brigit Roberts, and Sir Charles Gardner Hospital, Perth, Western Australia. A list of additional IRONMAN study collaborators is provided as Additional file 1.

Funding
The IRONMAN RCT was funded by a SHRAC Research Translation Project Grant 2012 (Round 6) ref: F-AA-12440, Department of Health, Government of Western Australia. Study drug was provided by Vifor Pharma as in-kind support without any involvement in the design of the study, analysis of results or preparation of manuscripts.

Availability of data and materials
The datasets generated during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
EL designed the research study, performed the research, analyzed the data and wrote the paper. SB designed the research study, performed the research and assisted in re-drafting the paper. WE, SF, CF, AH, AHO, JKO and TR designed the research study and assisted in re-drafting the paper. JF performed the research and assisted in re-drafting the paper. JG and RT contributed essential reagents and tools and assisted in writing the paper. DH, BDX, JM, ST and SW designed the research study, performed the research and assisted in re-drafting the paper. The ANZICS CTG provided critical appraisal, review and feedback of the IRONMAN programme of research and critical appraisal, feedback and editorial suggestions on the current manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Human Research Ethics Committee approval was obtained at all sites prior to commencement and prospective consent was obtained from all participants or their legal surrogates (SMHS HREC Ref 12/347).

Consent for publication
Not applicable.

Competing interests
AH has received industry-supplied funding for overseas lectures and travel from Vifor International AG and its subsidiaries of a total of approximately £60,000, from TEM International of a total of approximately £5000 and from UCB International of a total of approximately £9000 (all of it are not related to the subject matter). The other authors declare that they have no competing interests.

References
1. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Peres-Bota D, Investigators ABC. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288(12):1499–507.
2. Hayden SJ, Albert TJ, Watkins TR, Svensson ER. Anemia in critical illness: insights into etiology, consequences, and management. Am J Respir Crit Care Med. 2012;185(10):1094–57.
3. Lelubre C, Vincent JL. Red blood cell transfusion in the critically ill patient. Ann Intensive Care. 2011;1:43.
4. Litton E, Xiao J, Ho KM. Safety and efficacy of intra venous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. Bmj. 2013;347:f8422.
5. Investigators I, Litton E, Baker S, Erber WN, Farmer S, Ferrier J, French C, Gummer J, Hawkins D, Higgins A, et al. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomised blinded trial: a randomised trial of IV iron in critical illness. Intensive Care Med. 2016;42(11):1715–22.
6. Pieracci FM, Stovall RT, Jacouben B, Rodil M, Cappa A, Burlew CC, Holena DN, Maier R, Berry S, Jurkovich J, et al. A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness. Crit Care Med. 2014;42(9):2048–57.
7. Lasocki S, Baron G, Driss F, Masson P, Montravers P. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med. 2010;36(6):1044–8.
8. Litton E, Baker S, Erber W, French C, Ferrier J, Hawkins D, Higgins AM, Hofmann A, Keuleman BL, Farmer S, et al. The IRONMAN trial: a protocol for a multicentre randomised placebo-controlled trial of intravenous iron in intensive care unit patients with anaemia. Crit Care Resusc. 2014;16(4):285–90.
9. Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, et al. Association between serum hepcidin-25 and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrol (Carlton). 2017;7(2):548–54.
10. van Rijnsoever M, Galhenage S, Mollison L, Gummer J, Trengove R, Olynyk JK. Dysregulated erythropoietin, hepcidin, and bone marrow iron metabolism contribute to iron deficient anaemia in hepatitis C. J Interf Cytokine Res. 2016;36(11):650–4.
11. Steensma DP, Saru BJ, Sloan JA, Tomita DK, Loprinzi CL. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood. 2015;125(23):3669–71.
12. May S, Bigelow C. Modeling nonlinear dose-response relationships in epidemiologic studies: statistical approaches and practical challenges. Dose-Response. 2006;3(4):474–90.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Intensive Care Unit, Fiona Stanley Hospital, Perth, Western Australia 6065, Australia. 2School of Medicine, University of Western Australia, Perth, Western Australia 6009, Australia. 3Intensive Care Unit, Sir Charles Gardner Hospital, Perth, Western Australia 6009, Australia. 4School of Pathology, University of Western Australia, Perth, Western Australia 6009, Australia. 5Medical School, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia 6009, Australia. 6Western Health, Melbourne, Victoria, Australia. 7University of Melbourne, Melbourne, Victoria, Australia. 8Separation Science and Metabolomics Laboratory Metabolomics Australia (Western Australia node), Murdoch University, Perth, Western Australia, Australia. 9Intensive Care Unit, Joondalup Health Campus, Joondalup, Western Australia, Australia. 10Centre of Research Excellence for Patient Blood Management in Critical Illness and Trauma, Monash University, Melbourne, Victoria, Australia. 11Intensive Care Unit, Royal Perth Hospital, Perth, Western Australia 6000, Australia. 12School of Medicine, University of Western Australia, Perth, Western Australia 6009, Australia. 13University College London, London, UK. 14Intensive Care Unit, Fiona Stanley Hospital, Perth, Western Australia 6150, Australia.

Received: 13 July 2018 Accepted: 23 August 2018
Published online: 10 September 2018
13. Lim J, Miles L, Litton E. Intravenous iron therapy in patients undergoing cardiovascular surgery: a narrative review. J Cardiothorac Vasc Anesth. 2018; 3(32):1439–51.
14. Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood. 2016;127(23):2809–13.
15. Lasocki S, Longrois D, Montravers P, Beaumont C. Hepcidin and anemia of the critically ill patient: bench to bedside. Anesthesiology. 2011;114(3):688–94.
16. Prentice AM, Doherty CP, Abrams SA, Cox SE, Atkinson SH, Verhoef H, Armitage AE, Drakesmith H. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood. 2012;119(8):1922–8.
17. Tacke F, Nuraldeen R, Koch A, Strathmann K, Hutschenreuter G, Trautwein C, Strnad P. Iron parameters determine the prognosis of critically ill patients. Crit Care Med. 2016;44(6):1049–58.
Author/s:
Litton, E; Baker, S; Erber, W; Farmer, S; Ferrier, J; French, C; Gummer, J; Hawkins, D; Higgins, A; Hofmann, A; De Keulenaer, B; McMorrow, J; Olynyk, JK; Richards, T; Towler, S; Trengove, R; Webb, S

Title:
Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study

Date:
2018-09-10

Citation:
Litton, E., Baker, S., Erber, W., Farmer, S., Ferrier, J., French, C., Gummer, J., Hawkins, D., Higgins, A., Hofmann, A., De Keulenaer, B., McMorrow, J., Olynyk, JK, Richards, T., Towler, S., Trengove, R. & Webb, S. (2018). Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study. JOURNAL OF INTENSIVE CARE, 6 (1), https://doi.org/10.1186/s40560-018-0328-2.

Persistent Link:
http://hdl.handle.net/11343/271184

File Description:
Published version

License:
CC BY